Literature DB >> 15673768

Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.

Annemarie Borst1, Maria T Raimer, David W Warnock, Christine J Morrison, Beth A Arthington-Skaggs.   

Abstract

Five azole-susceptible Candida glabrata isolates obtained before 1975 became resistant to fluconazole, itraconazole, and voriconazole within 4 days of in vitro fluconazole exposure. This cross-resistance was stable for at least 4 months after removal of fluconazole and was associated with increased CgCDR1 and CgCDR2 expression.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15673768      PMCID： PMC547350          DOI： 10.1128/AAC.49.2.783-787.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

2.  Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors.

Authors:  K W Henry; J T Nickels; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Reversible fluconazole resistance in Candida albicans: a potential in vitro model.

Authors:  H M Calvet; M R Yeaman; S G Filler
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 4.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.

Authors:  Dominique Sanglard; Frank C Odds
Journal:  Lancet Infect Dis       Date:  2002-02       Impact factor: 25.071

5.  The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

Authors:  D Sanglard; F Ischer; D Calabrese; P A Majcherczyk; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

Authors:  D J Diekema; S A Messer; A B Brueggemann; S L Coffman; G V Doern; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.

Authors:  Spencer W Redding; William R Kirkpatrick; Stephen Saville; Brent J Coco; William White; Annette Fothergill; Michael Rinaldi; Tony Eng; Thomas F Patterson; Jose Lopez-Ribot
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

8.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria.

Authors:  Rupinder Kaur; Irene Castaño; Brendan P Cormack
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Function of Candida glabrata ABC transporter gene, PDH1.

Authors:  Koichi Izumikawa; Hiroshi Kakeya; Huei-Fung Tsai; Brian Grimberg; John E Bennett
Journal:  Yeast       Date:  2003-02       Impact factor: 3.239
View more
  34 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

Review 2.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

Review 5.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

6.  Azole resistance of Candida glabrata in a case of recurrent fungemia.

Authors:  Brunella Posteraro; Mario Tumbarello; Marilena La Sorda; Teresa Spanu; Enrico Maria Trecarichi; Flavia De Bernardis; Giancarlo Scoppettuolo; Maurizio Sanguinetti; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

7.  Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.

Authors:  Dominique Sanglard; Alix T Coste
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

8.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

9.  The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

10.  Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.

Authors:  Vladimír Hrabovský; Victoria Takáčová; Eva Schréterová; Lydia Pastvová; Zuzana Hrabovská; Katarina Čurová; Leonard Siegfried
Journal:  Folia Microbiol (Praha)       Date:  2017-03-30       Impact factor: 2.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.